rs7234029 — PTPN2

Intronic PTPN2 variant increasing susceptibility to Crohn's disease, rheumatoid arthritis, and juvenile idiopathic arthritis

See your personal result for PTPN2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PTPN2 — The Phosphatase That Keeps Your T-Cells in Check

Inside every T-cell, a molecular brake pedal controls how aggressively the cell responds to immune activation signals. That brake is TC-PTP (T-cell protein tyrosine phosphatase)11 TC-PTP (T-cell protein tyrosine phosphatase)
A non-receptor protein tyrosine phosphatase encoded by PTPN2 that dephosphorylates and inactivates JAK1, JAK3, STAT1, STAT3, and STAT5 — the core signaling proteins that drive T-cell proliferation and cytokine production. When TC-PTP functions at full strength, it restrains T-cell activation to a level proportional to the actual threat. When TC-PTP expression is reduced, that restraint weakens — the immune system activates more readily, sustains responses longer, and is more prone to misdirecting attacks against self-tissue.

The Evidence

The strongest body of evidence for rs7234029 comes from inflammatory bowel disease and autoimmune arthritis. A meta-analysis of 17 studies22 meta-analysis of 17 studies
Zhang JX et al., Inflamm Res 2014; 18,308 cases and 20,406 controls found that G allele carriers had a 36% increased risk of Crohn's disease (OR=1.36, 95% CI 1.16–1.59, I²=0%), a homogeneous result across studies suggesting robust replication. A German case-control study33 German case-control study
Glas J et al., PLoS One 2012; 905 CD patients, 318 UC patients, 908 controls found p=1.30×10⁻³ (OR 1.35) for rs7234029 and Crohn's disease specifically, and made the clinically relevant observation that the variant was associated with the stricturing disease phenotype (B2) in CD patients (p=6.62×10⁻³) — the most aggressive intestinal phenotype characterized by fibrostenotic lesions.

In the joints, the evidence is equally robust. A multi-disease GWAS of shared autoimmunity loci Thompson SD et al., Arthritis Rheum 2010; 809 JIA cases, 3,535 controls with replication in 1,015 additional JIA cases44 Thompson SD et al., Arthritis Rheum 2010; 809 JIA cases, 3,535 controls with replication in 1,015 additional JIA cases found rs7234029 OR=1.35, P=1.86×10⁻¹⁰, confirming PTPN2 as one of seven validated shared autoimmune loci spanning RA, T1D, Crohn's disease, and multiple sclerosis. An independent European RA GWAS Cobb JE et al., PLoS One 2013; 4,286 RA patients, 5,642 controls55 Cobb JE et al., PLoS One 2013; 4,286 RA patients, 5,642 controls found genome-wide significant evidence for rs7234029 at P=4.4×10⁻⁹, describing PTPN2 as "a pan-autoimmune susceptibility gene" in Caucasian populations.

The variant also has pharmacogenomic relevance. A Crohn's disease treatment study Hoffmann P et al., Genes Basel 2021; 379 CD patients66 Hoffmann P et al., Genes Basel 2021; 379 CD patients found that rs7234029 G allele carriers had substantially higher non-response rates to anti-IL-12/23 therapy (89.9% vs 67.6%, p=0.005). In rheumatoid arthritis, a prospective cohort study Conigliaro P et al., PLoS One 2017; 171 RA patients77 Conigliaro P et al., PLoS One 2017; 171 RA patients found the PTPN2 variant associated with reduced EULAR response to adalimumab at 6 months.

Practical Actions

For G allele carriers, the primary implication is a modestly elevated risk for Crohn's disease, rheumatoid arthritis, and juvenile idiopathic arthritis. These conditions share early warning signs — unexplained joint pain, changes in bowel habits, fatigue — that are worth taking seriously and evaluating promptly. Early diagnosis and treatment initiation before significant intestinal or joint damage has occurred meaningfully improves outcomes in all three conditions. For individuals who already carry a diagnosis of CD or RA, the G allele's association with reduced response to anti-IL-12/23 therapy (in CD) and anti-TNF therapy (in RA) is emerging evidence — not yet sufficient for clinical decision-making alone — but worth discussing with a specialist when treatment options are being considered.

Interactions

rs7234029 is one of three commonly studied PTPN2 variants in IBD and autoimmune disease. The other two — rs1893217 (intronic, OR=1.45 for CD in meta-analysis) and rs2542151 (intronic, OR=1.22 for CD) — tag different aspects of PTPN2 regulation and are not in strong LD with rs7234029. Carrying the risk allele at multiple PTPN2 variants compounds the risk beyond any single variant alone. Additionally, PTPN2 operates in the same pathway as STAT3 and JAK1/JAK3 — the targets of tofacitinib and other JAK inhibitors approved for IBD and RA. This makes PTPN2 variants biologically relevant to JAK inhibitor pharmacogenomics, though clinical guidelines have not yet incorporated PTPN2 genotyping for JAK inhibitor selection.

Genotype Interpretations

What each possible genotype means for this variant.

AA Normal

Common genotype — no elevated autoimmune risk at this locus

You carry two copies of the A allele at rs7234029, the common genotype in European and South Asian populations (~54% globally). This is not associated with elevated risk for PTPN2-linked autoimmune conditions at this locus.

AG Intermediate

One G allele associated with elevated Crohn's disease risk

You carry one copy of the G allele at rs7234029. This is the most common risk-allele-carrying genotype, present in approximately 39% of people globally and roughly 24% of Europeans. Meta-analysis data across 18,000+ cases show that G allele carriers have approximately 36% elevated risk for Crohn's disease. These are relative risk increases on a low baseline, meaning most heterozygotes remain unaffected throughout life.

GG High Risk

Two G alleles associated with the highest risk at this locus for Crohn's disease and inflammatory arthritis

The pharmacogenomic signal is clinically relevant for GG carriers who develop CD or RA. In a Heidelberg cohort, G allele carriers had 89.9% non-response to anti-IL-12/23 therapy vs 67.6% in non-carriers (p=0.005). Validation in larger cohorts is ongoing, but this finding is worth raising with a gastroenterologist if CD is diagnosed.